Sort by
Items per page

Send to

Choose Destination

Search results

Items: 21


Standardization of Flow Cytometric Immunophenotyping for Hematological Malignancies: The FranceFlow Group Experience.

Solly F, Angelot-Delettre F, Ticchioni M, Geneviève F, Rambaud H, Baseggio L, Plesa A, Debliquis A, Garnache-Ottou F, Roggy A, Campos L, Aanei C, Rosenthal-Allieri A, Georget MT, Lachot S, Jacob MC, Robillard N, Wuilleme S, Andre-Kerneis E, Cornet E, Salaun V, Bennami H, Lhoumeau AC, Arnoulet C, Jacqmin H, Neyman N, Latger-Cannard V, Massin F, Lainey E, Le Garff-Tavernier M, Costopoulos M, Roussel M, Mayeur-Rousse C, Eischen A, Raggeneau V, Derrieux C, Maurer M, Asnafi V, Trinquand A, Brouzes C, Lhermitte L.

Cytometry A. 2019 Sep;95(9):1008-1018. doi: 10.1002/cyto.a.23844. Epub 2019 Jul 31.


Over 20 years of treatment-free remission after interferon-alpha monotherapy for chronic myeloid leukemia.

Bloch J, Spertini O, Stucki A, Solly F, Blum S.

Leuk Res. 2018 Oct;73:103-104. doi: 10.1016/j.leukres.2018.09.002. Epub 2018 Sep 11. No abstract available.


Prognostic value of multicenter flow cytometry harmonized assessment of minimal residual disease in acute myeloblastic leukemia.

Lacombe F, Campos L, Allou K, Arnoulet C, Delabarthe A, Dumezy F, Feuillard J, Geneviève F, Guérin E, Guy J, Jouault H, Lepelley P, Maynadié M, Solly F, Ballon OW, Preudhomme C, Baruchel A, Dombret H, Ifrah N, Béné MC; Groupe d'Etude Immunologique des Leucémies (GEIL).

Hematol Oncol. 2018 Apr;36(2):422-428. doi: 10.1002/hon.2488. Epub 2017 Dec 7.


TET2 exon 2 skipping is an independent favorable prognostic factor for cytogenetically normal acute myelogenous leukemia (AML): TET2 exon 2 skipping in AML.

Mohamed AM, Balsat M, Koering C, Maucort-Boulch D, Boissel N, Payen-Gay L, Cheok M, Mortada H, Auboeuf D, Pinatel C, El-Hamri M, Tigaud I, Hayette S, Dumontet C, Cros E, Flandrin-Gresta P, Nibourel O, Preudhomme C, Thomas X, Nicolini FE, Solly F, Guyotat D, Campos L, Michallet M, Ceraulo A, Mortreux F, Wattel E.

Leuk Res. 2017 May;56:21-28. doi: 10.1016/j.leukres.2017.01.012. Epub 2017 Jan 16.


An miRNA-DNMT1 Axis Is Involved in Azacitidine Resistance and Predicts Survival in Higher-Risk Myelodysplastic Syndrome and Low Blast Count Acute Myeloid Leukemia.

Solly F, Koering C, Mohamed AM, Maucort-Boulch D, Robert G, Auberger P, Flandrin-Gresta P, Adès L, Fenaux P, Kosmider O, Tavernier-Tardy E, Cornillon J, Guyotat D, Campos L, Mortreux F, Wattel E.

Clin Cancer Res. 2017 Jun 15;23(12):3025-3034. doi: 10.1158/1078-0432.CCR-16-2304. Epub 2016 Nov 23.


One tube with eight antibodies for 14-part bone marrow leukocyte differential using flow cytometry.

Jacob MC, Souvignet A, Pont J, Solly F, Mondet J, Kesr S, Pernollet M, Dumestre-Perard C, Campos L, Cesbron JY.

Cytometry B Clin Cytom. 2017 Jul;92(4):299-309. doi: 10.1002/cyto.b.21369. Epub 2016 May 6.


CD180 expression in B-cell lymphomas: A multicenter GEIL study.

Mayeur-Rousse C, Guy J, Miguet L, Bouyer S, Geneviève F, Robillard N, Solly F, Maar A, Bené MC, Mauvieux L; GEIL (Groupe d'Etude Immunologique des Leucémies).

Cytometry B Clin Cytom. 2016 Sep;90(5):462-6. doi: 10.1002/cyto.b.21325. Epub 2015 Oct 6.


Oncogene- and drug resistance-associated alternative exon usage in acute myeloid leukemia (AML).

Mohamed AM, Balsat M, Thenoz M, Koering C, Payen-Gay L, Cheok M, Mortada H, Auboeuf D, Pinatel C, El-Hamri M, Dumontet C, Cros E, Flandrin-Gresta P, Nibourel O, Preudhomme C, Michallet M, Thomas X, Nicolini F, Solly F, Guyotat D, Campos L, Wattel E, Mortreux F.

Oncotarget. 2016 Jan 19;7(3):2889-909. doi: 10.18632/oncotarget.3898.


In vivo and in vitro sensitivity of blastic plasmacytoid dendritic cell neoplasm to SL-401, an interleukin-3 receptor targeted biologic agent.

Angelot-Delettre F, Roggy A, Frankel AE, Lamarthee B, Seilles E, Biichle S, Royer B, Deconinck E, Rowinsky EK, Brooks C, Bardet V, Benet B, Bennani H, Benseddik Z, Debliquis A, Lusina D, Roussel M, Solly F, Ticchioni M, Saas P, Garnache-Ottou F.

Haematologica. 2015 Feb;100(2):223-30. doi: 10.3324/haematol.2014.111740. Epub 2014 Nov 7.


How mRNA is misspliced in acute myelogenous leukemia (AML)?

Mohamed AM, Thénoz M, Solly F, Balsat M, Mortreux F, Wattel E.

Oncotarget. 2014 Oct 30;5(20):9534-45. Review.


[CXCR4: a new therapeutic target of the leukaemic cell? Role of the SDF-1/CXCR4 axis in acute myeloid leukaemia].

Tavernier E, Aanei C, Solly F, Flandrin-Gresta P, Campos L, Guyotat D.

Bull Cancer. 2014 Jun;101(6):593-604. doi: 10.1684/bdc.2014.1925. Review. French.


Comparable flow cytometry data can be obtained with two types of instruments, Canto II, and Navios. A GEIL study.

Solly F, Rigollet L, Baseggio L, Guy J, Borgeot J, Guérin E, Debliquis A, Drenou B, Campos L, Lacombe F, Béné MC.

Cytometry A. 2013 Dec;83(12):1066-72. doi: 10.1002/cyto.a.22404. Epub 2013 Oct 21.


Heat Shock Protein 90 is overexpressed in high-risk myelodysplastic syndromes and associated with higher expression and activation of Focal Adhesion Kinase.

Flandrin-Gresta P, Solly F, Aanei CM, Cornillon J, Tavernier E, Nadal N, Morteux F, Guyotat D, Wattel E, Campos L.

Oncotarget. 2012 Oct;3(10):1158-68.


HSP90 inhibition results in apoptosis of Philadelphia acute lymphoblastic leukaemia cells: an attractive prospect of new targeted agents.

Tavernier E, Flandrin-Gresta P, Solly F, Rigollet L, Cornillon J, Augeul-Meunier K, Stephan JL, Montmartin A, Viallet A, Guyotat D, Campos L.

J Cancer Res Clin Oncol. 2012 Oct;138(10):1753-8. Epub 2012 Jun 17.


Accurate detection of the tumor clone in peripheral T-cell lymphoma biopsies by flow cytometric analysis of TCR-Vβ repertoire.

Salameire D, Solly F, Fabre B, Lefebvre C, Chauvet M, Gressin R, Corront B, Ciapa A, Pernollet M, Plumas J, Macintyre E, Callanan MB, Leroux D, Jacob MC.

Mod Pathol. 2012 Sep;25(9):1246-57. doi: 10.1038/modpathol.2012.74. Epub 2012 May 25.


CD304 is preferentially expressed on a subset of B-lineage acute lymphoblastic leukemia and represents a novel marker for minimal residual disease detection by flow cytometry.

Solly F, Angelot F, Garand R, Ferrand C, Seillès E, Schillinger F, Decobecq A, Billot M, Larosa F, Plouvier E, Deconinck E, Legrand F, Saas P, Rohrlich PS, Garnache-Ottou F.

Cytometry A. 2012 Jan;81(1):17-24. doi: 10.1002/cyto.a.21162. Epub 2011 Nov 3.


Mutual benefits of B-ALL and HLDA/HCDM HLDA 9th Barcelona 2010.

Faure GC, Amsellem S, Arnoulet C, Bardet V, Campos L, De Carvalho-Bittencourt M, de Labarthe A, Eischen A, Feuillard J, Fossat C, Ottou FG, Guérin E, Guy J, Jouault H, Kuhlein E, Lacombe F, Lainey E, Maynadié M, Noguera ME, Roussel M, Solly F, Ballon OW, Béné MC; GEIL workshop.

Immunol Lett. 2011 Jan 30;134(2):145-9. doi: 10.1016/j.imlet.2010.10.008. Epub 2010 Oct 15.


Efficient characterization of the TCR repertoire in lymph nodes by flow cytometry.

Salameire D, Le Bris Y, Fabre B, Fauconnier J, Solly F, Pernollet M, Bonnefoix T, Leroux D, Plumas J, Jacob MC.

Cytometry A. 2009 Sep;75(9):743-51. doi: 10.1002/cyto.a.20767.


Tissue-type plasminogen activator has antiangiogenic properties without effect on tumor growth in a rat C6 glioma model.

Solly F, Fish R, Simard B, Bolle N, Kruithof E, Polack B, Pernod G.

Cancer Gene Ther. 2008 Oct;15(10):685-92. doi: 10.1038/cgt.2008.36. Epub 2008 Jun 6.


Genetics and epigenetics of 1q rearrangements in hematological malignancies.

Fournier A, Florin A, Lefebvre C, Solly F, Leroux D, Callanan MB.

Cytogenet Genome Res. 2007;118(2-4):320-7. Review.


More on: on the molecular mechanisms for the highly procoagulant pattern of C6 glioma cells.

Solly F, Pernod G.

J Thromb Haemost. 2006 Oct;4(10):2289-90. Epub 2006 Jul 17. No abstract available.

Supplemental Content

Support Center